Research Article
Safety and Efficacy of Ferula asafoetida in Functional Dyspepsia: A Randomized, Double-Blinded, Placebo-Controlled Study

K. N. Mala, 1 Jestin Thomas, 2 Das S. Syam, 3 Balu Maliakel, 3 and I. M. Krishnakumar 3

1 Sri Rama Hospital, Fort road, Doddaballapur, Bangalore, India
2 Leads Clinical Research & Bio Services Pvt. Ltd., Bangalore, India
3 R&D Centre, Akay Flavours & Aromatics Pvt. Ltd., Kerala, India

Correspondence should be addressed to I. M. Krishnakumar; krishnakumar.im@akay-group.com

Received 25 April 2018; Revised 4 July 2018; Accepted 2 August 2018; Published 26 August 2018

1. Introduction

Functional dyspepsia (FD) is one of the most common functional gastrointestinal disorders (FGIDs) that have been shown to affect the gastroduodenal region of the gastrointestinal (GI) tract with no identifiable structural lesions [1]. FD is normally characterized with discomforts such as bloating, early satiety, postprandial fullness, belching, heart burn, indigestion, and epigastric pain leading to the poor quality of life [2, 3]. Though it does not cause mortality, FD is a costly gastroenterology practice which is highly prevalent in all populations with a relatively increased rate of incidence among females [3, 4]. In the United States, the prevalence rate has been found to be more than 40% with an expense of $18.4 billion towards the average healthcare cost in 2009 [5]. An epidemiological study in Europe has also demonstrated 40% dyspepsia prevalence with multiple medical visits and medication for more than 50% of the individuals [6].

A number of factors such as duodenal eosinophilia, psychiatric distress, gastroduodenal dysfunction, Helicobacter pylori infection, smoking, alcoholism, chronic usage of non-steroidal anti-inflammatory drugs (NSAIDs), and sedentary life style have very often been delineated to the pathogenesis of FD [1, 7–9]. Despite varying results of controlled clinical trials, the current pharmacologic treatment modalities include the use of Helicobacter pylori inhibitors, acid suppressants, proton pump inhibitors, antidepressants, antacids, and prokinetics [10–13]. Gastric acid suppression and enhancement of gastrointestinal motility are the underlying mechanisms of most of these drugs. However,
The present study is a formulation of asafoetida oleo-gum-resin with widespread use of asafoetida gum. Asafin used in the main physicochemical and organoleptic hurdles associated compounds [10 to 20% (w/v)] have been identified as the due to relatively high levels of essential oil rich in sulphur orders. Gummynature, pungency, and the unpleasant odour peuticefficacy of asafoetida gum against any of the health dis-
clinical evaluations have so far been reported on the thera-
and gastroprotective activities of asafoetida [30]. However, no
strated the antioxidant, antiviral, antimicrobial, antidiabetic,
nitric oxide [29]. Pharmacological studies have also demon-
ested the action on excitatory pathways such as cholineric [24], histamnergic
[25], or mimicking the action of inhibitory systems such as adrenergic [26], purinergic [27], GABAergic [28], and/or nitric oxide [29]. Pharmacological studies have also demonstrated the antioxidant, antiviral, antimicrobial, anti-diabetic, and gastroprotective activities of asafoetida [30]. However, no clinical evaluations have so far been reported on the therapeutic efficacy of asafoetida gum against any of the health dis-
orders. Gummy nature, pungency, and the unpleasant odour due to relatively high levels of essential oil rich in sulphur compounds [10 to 20% (w/v)] have been identified as the main physicochemical and organoleptic hurdles associated with the wide spread use of asafoetida gum. Asafin used in the present study is a formulation of asafoetida oleo-gum-resin encapsulated with soluble dietary fibre (galactomannans), isolated from fenugreek seeds (Trigonella foenum gracum) [31]. Fenugreek galactomannans are good prebiotics with hypolipidemic, hypoglycemic, and gastroprotective effects [32]. High viscosity, gel formation, encapsulation efficiency, mucoadhesive nature, and gastroretentive property of fenugreek galactomannans have already been established as a good vehicle for the formulation of oral delivery solid dosage forms of bioactive molecules [33].

2. Materials and Methods

2.1. Subjects and Study Design. The study was conducted at M/s Sri Rama Hospital, Bangalore, India, under the supervision of a qualified medical doctor, following a randomized, double-blinded, placebo-controlled design. The study was in strict accordance with the clinical research guidelines of Government of India following the protocol approved (dated 15/07/2016) by the registered ethical committee (Reg. No. ECR/184/Int/KA/2014) and was retrospectively registered in clinical trial registry of India at http://ctri.nic.in/ (CTRI/2018/ 01/011149). The subjects were selected from the out patients who approached the doctor for medical consultation on gastrointestinal disorders. Those subjects who have been characterized to have functional dyspepsia based on Rome III Diagnostic Criteria were enrolled in the study with a written consent [34]. According to Rome III criteria, subjects with no suspected structural diseases such as gastric ulcers, but characterized to have symptoms of bothersome postprandial fullness, early satiation, epigastric pain, and epigastric burning, were identified to have FD. Details of inclusion and exclusion criteria followed in the study were given in Table 1. The power used to calculate sample size is 80% and got a minimum sample size of 40 required for the study. A total of 60 subjects (aged between 25 and 55 years) were enrolled and provided with a unique three-digit randomization code.

| Table 1: Inclusion and exclusion criteria used for subject’s eligibility. |
|-----------------------------|
| **Inclusion Criteria** |
| (i) Age 25-60 years (both inclusive) |
| (ii) Male and female subjects |
| (iii) Fulfilling Rome III Diagnostic Criteria for Functional Dyspepsia |
| (iv) Must meet the criteria for 3 months and must begin experiencing symptoms for at least 6 months before diagnosis. |
| (v) Subject willing to give written informed consent |

| **Exclusion Criteria** |
|--------------------------|
| (i) History of Peptic ulcer, Gastro-oesophageal Reflux Disease, Gastrointestinal surgery or any other clinically significant gastrointestinal disease |
| (ii) Psychiatric illness |
| (iii) Pregnant or lactating women |
| (iv) History of congestive heart failure or uncontrolled hypertension |
| (v) Subjects with abnormal haematological or biochemical parameters |
| (vi) Subjects who have taken antibiotics or any other drugs in last 2 weeks whose primary site of action is in the Gastrointestinal tract |
| (vii) Any condition that in opinion of the investigator, does not justify the subjects’ participation in the study |
Figure 1: Cohort diagram showing study design.

The protocol used in the present study was depicted in Figure 1. Total study period was 30 days. Subjects were requested to visit their designated study site on three different occasions, namely, visit 1- screening and enrolment; visit 2- baseline/randomization (Day 0); and visit 3- end of study (EOS) (Day 30). The baseline characteristics are provided in Table 3. A physical examination and laboratory tests (including red-cell counts, packed cell volume, mean corpuscular volume, liver-function tests and renal function tests), were performed during visit 1 (Screening) and on visit 3 (Day 30). During visit 1, twelve subjects refused to participate in the study. Sequentially numbered airtight high density polyethylene containers each containing 90 numbers of 250 mg capsules of either Asafin or placebo were provided on visit 1 (Day 0) and instructed to take one capsule before the breakfast and another one before dinner (250 mg × 2/day). The degree of adherence of the subjects was assessed by “count pill” strategy. Asafin has the characteristic smell of asafoetida oleo-gum-resin and the placebo was MCC. In order to have the asafoetida oleo-gum-resin like smell, MCC was plated with 0.01% of asafoetida oleo-gum-resin. Thus, each bottle (Asafin and placebo) of capsules was managed was plated with 0.01% of asafoetida oleo-gum-resin. Blinding efficacy was assessed by giving a chance to guess the group to which each subject was assigned to ensure the smell identification is possible or not. Subjects were monitored on a weekly basis through regular telephonic follow-ups and short message services.

2.2. General. The proprietary formulation of asafoetida-gum-resin (patent pending and registered formulation as ‘Asafin’®) was obtained from M/s Akay Flavours & Aromatics Ltd., Cochin, India, along with a detailed certificate of analysis indicating its relative composition of asafoetida gum, dietary fibre, volatile oil, and ferulic acid content [31]. Safety parameters including pesticides, microbial counts, mycotoxins, and heavy metal content of both Asafin and placebo (microcrystalline cellulose, MCC) were analyzed as per USFDA requirements for dietary supplements [35]. Asafin was prepared from Iranian asafoetida and voucher specimen (AK-ASF-01) was deposited at the Herbarium of M/s Akay Flavours & Aromatics Ltd., Cochin, India. Safety of Asafin was assessed by lethal dose (LD_{50}) and subacute repeated dose 28-day toxicity study on Wistar rats [31]. Volatile oil content was measured using a standardized and approved method of American Spice Trade Association (ASTA, 1997) [36]. Ferulic acid standard was obtained from Sigma-Aldrich, Bangalore, India, and estimated by a high performance liquid chromatography (HPLC). Shimadzu model LC 20 AT, with an M20A photo diode array (PDA) detector (Shimadzu Analytical India Pvt. Ltd., Mumbai, India), fitted with a reverse phase C18 column (250 × 4.6 mm, 3 μm) (Phenomenex, Hyderabad, India) was used for analysis. Water with 10% acetic acid and acetonitrile with 20% acetic acid were as the mobile phases and monitored at 319 nm. Scanning electron micrograph was performed on SEM Jeol 6390 LA equipment (JEOL Ltd., Tokyo, Japan).

2.3. Efficacy Determination. The efficacy end points were primarily assessed by three validated questionnaires: Gastrointestinal Symptom Rating Scale (GSRS) [37, 38], Glasgow Dyspepsia Severity Score (GDSS) [39, 40], and Nepean Dyspepsia Index (NDI) [41, 42]. The questionnaires were provided at visit 2 (Day 0) and visit 3 (Day 30) of the study. GSRS consists of a seven-point graded Likert-type scale where “1” represents the absence of troublesome symptoms and “7” represents the most troublesome symptoms [43]. GDSS provides a global measurement of the severity of dyspepsia using seven questions from seven different categories with regard to upper gastrointestinal symptoms. The present study employed a modified version of GDSS where 0 was the minimum possible score and 20 was the maximum score, in the ascending order of discomfort level [39]. NDI is one of the most recent disease-specific indexes for dyspepsia, which measures symptoms and health-related quality of life [44]. It originally contained 42 items designed to measure the impact of FD on a subject’s ability to engage in relevant aspects of their life [41]. The present study employed the short form (NDI-SF) of NDI having 10 items, with a 5-point Likert scale ranging from 0 (not at all or not applicable) to 4 (extremely applicable) [45].

2.4. Safety Evaluation. The primary safety and tolerability of Asafin at the present dosage of (250 mg × 2/day) was evaluated by specifically collecting the individual data regarding any adverse reactions, clinical changes, or discomforts. Haematological and biochemical parameters at the beginning and at the end of the study were also conducted as a measure of safety. Red blood cell (RBC) count, haemoglobin level (Hb), packed cell volume (PCV), mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH), and mean corpuscular haemoglobin concentration (MCHC) were determined using a haematology analyzer (Model-Diatron, Wien, Austria). Plasma was separated by centrifugation at 11,950g for 10 min at 4°C and stored for a maximum of two days at −20°C for biochemical analysis. Biochemical parameters such as glutamate oxaloacetate transaminase (SGOT),
glutamate pyruvate transaminase (SGPT), and alkaline phosphatase (ALP) levels and serum creatinine were analyzed by following the assay kits provided by M/s Agappe Diagnostics Pvt. Ltd., Bangalore, India. Random blood sugar levels were analyzed by ACCU-CHEK active glucose test strips and glucose meter (Roche Diagnostic GmbH, Mannheim, Germany).

2.5. Statistical Analysis. Statistical analyses were carried out using the Statistical Package for Social Science (SPSS Inc. Chicago, IL, USA) version 17.0. Total sample size at the end of study was 43. The efficacy end points included the comparison of data at the baseline and at the end of the study (within group comparison) and also the comparison with the placebo group (between group comparisons). Within group comparison was done with paired sample t-test and between group comparisons were done using independent sample t-test and \( p \leq 0.05 \) was considered to be significant. The results were presented as mean ± SEM. 95% CI values are also provided. Mean difference was compared by using independent sample t-test.

3. Results

Iranian asafoetida oleo-gum-resin was employed for the preparation of Asafin used in the present study. Gel-phase dispersion followed by microencapsulation of asafoetida oleo-gum-resin on fenugreek soluble fibre (galactomannans) matrix provided water soluble free-flowing granules of Asafin with particle size of around 250±50\( \mu \)m suitable for the manufacture of capsules, tablets, and softgels. Water based preparation process with no organic solvents and synthetic chemicals provided a unique green formulation suitable for food and nutraceutical applications. HPLC finger printing revealed the stability of Asafin as compared to asafoetida gum with 1.5% of ferulic acid content (Figures 2(a) and 2(b)). Stable encapsulation of asafoetida gum within the fenugreek soluble dietary fibre was clear from the SEM photographs (Figure 2(c)). Upon detailed analysis of the nutritional composition and food safety, parameters demonstrated the adherence of Asafin to international regulation for use as dietary supplements (Table 2).

3.1. Effect of Asafin on FD Symptoms and Severity Score. The present study employed FD symptoms rating scales (GSRS, GDSS, and NDI) to evaluate the efficacy of Asafin supplementation on individual dyspepsia symptoms and overall severity score as compared to placebo and baseline. A significant \( (p \leq 0.001) \) reduction (51.6%) in overall symptoms severity score was observed when GSRS scores of Asafin group were compared with placebo (Table 4). Within group comparison of GSRS scores with that at the end of the study period using paired sample t-test showed a significant reduction in Asafin group (95% confidence interval: from 25.29; 44.19±0.85 to 18.90±0.67; p ≤ 0.001) as compared to the placebo (95% confidence interval: from −6; 45.09±0.72 to 39.09±0.67; p ≤ 0.001) (Figure 3(a)). Between group comparison showed no significant difference between baseline values of placebo with Asafin treated group but showed significant difference in the end of study values when compared to placebo (Table 4; 95% CI 2.61, 54.98). Inter-group comparison also showed a significant reduction in GDSS score of the Asafin group (\( p \leq 0.001 \); 47%) as compared to the placebo (95% confidence interval: placebo...
Figure 3: (a) Gastrointestinal Symptom Rating Scale (GSRS); (b) Glasgow Dyspepsia Severity Score (GDSS); (c) Nepean Dyspepsia Index-Short Form (NDI-SF). Values are expressed as mean ± SEM. The values not sharing a superscript significantly differ at p ≤ 0.001.

Table 2: Physicochemical characteristics of Asafin.

| Parameters               | Test results                          |
|--------------------------|---------------------------------------|
| Colour and Appearance    | Off-White free flowing powder         |
| Odour                    | Mild characteristic                   |
| Solubility               | Soluble in water upon homogenisation  |
| Moisture (%)             | 4.2                                   |
| Bulk density (g mL⁻¹)    | 0.56                                  |
| Volatile oil content (%) | 3.4                                   |
| Nutrition Facts/100 g    |                                       |
| Carbohydrates            | 82.0 g                                |
| Proteins                 | 6.1g                                  |
| Dietary fibre            | 6.1g                                  |
| Fat (hexane solubles)    | 3.2g                                  |
| Energy                   | 381.2kcal                             |

Table 3: Baseline characteristics of study subjects.

| Characteristics         | Baseline (N=43) |
|-------------------------|-----------------|
| Age (years)             | 29.46 ± 6.24    |
| Height (Cm)             | 158.7 ± 5.3     |
| Weight (kg)             | 60.5 ± 6.4      |
| BMI (kg/m²)             | 24.22 ± 2.37    |
| Systolic BP (mmHg)      | 114.07 ± 7.34   |
| Diastolic BP (mmHg)     | 70.20 ± 8.74    |
| Pulse                   | 70.13 ± 6.73    |

Data expressed as mean ± SD.

9.22±0.23; Asafin 4.80±0.17) (Table 4). Almost 69% subjects in the Asafin group reported significant reduction in the frequency of FD symptoms and 87% reported no usage of any synthetic drugs during the course of the study. Between group comparison showed no significant difference between baseline values of placebo with Asafin treated group but showed significant difference in the end of study values when compared to placebo (Table 4; 95% CI 1.70, 28.02).

Analysis of the NDI scores also confirmed a significant (p ≤ 0.001) reduction (38.67%) on overall symptoms in Asafin group as compared to the placebo (Table 4). Inner group comparison with respect to the baseline and end of the study demonstrated a relative difference of -16.57 (from 37.28±0.71 to 20.71±1.09) in Asafin group and -5.32 (from 39.09±1.28 to 33.77±1.07) in case of placebo (Figure 3(c)). Intergroup comparison indicated a difference of -13.06 in NDI score when the scores of the Asafin with placebo group at the end of the study were compared (95% confidence interval: 37.28±0.71 to 20.71±1.09). Between group comparison showed no significant difference between baseline values of placebo with Asafin treated group but showed significant difference in end of study values when compared to placebo (Table 4; 95% CI 2.06, 35.08).

A comparison of all the three symptoms rating scores (GSRS, GDSS, and NDI) indicated similar baseline values for both the Asafin and placebo groups, with no significant differences (Table 4). But, at the end of the study, Asafin group showed significant reduction in all the three scores (81% of subjects), indicating its primary efficacy against FD (Figure S1). When the individual symptoms were monitored,
### Table 4: Statistical comparison of dyspepsia indexing scores.

| Name of Tool | Intergroup comparison based on independent sample t-test | Inner group comparison based on paired sample t-test | 95% CI Values | Mean difference comparison of variables using independent sample t-test | p-value |
|--------------|--------------------------------------------------------|-----------------------------------------------------|---------------|-------------------------------------------------------------------|---------|
| GSRS         | Time of Observation | Placebo | Asafin | Groups | Baseline | End of Study | Values | |
| Baseline     | 45.33±0.77 | 43.91±0.78 | Placebo | 45.09±0.72 | 39.09±0.07 | 2.61 | 6.00±0.33 | |
| End of study | 39.09±0.67 | 18.90±0.67 | Asafin | 44.29±0.85 | 18.40±0.67 | 54.98 | 25.28±0.89 | |
| GDSS         | Time of Observation | Placebo | Asafin | Groups | Baseline | End of Study | Values | |
| Baseline     | 10.79±0.20 | 10.45±0.21 | Placebo | 10.77±0.22 | 9.22±0.23 | 1.70 | 1.90±0.20 | p<0.001 |
| End of study | 9.22±0.23 | 4.80±0.17 | Asafin | 10.47±0.22 | 4.80±0.17 | 28.02 | 5.66±0.24 | |
| NDI          | Time of Observation | Placebo | Asafin | Groups | Baseline | End of Study | Values | |
| Baseline     | 38.95±1.20 | 37.25±0.68 | Placebo | 39.09±1.28 | 33.77±1.07 | 2.06 | 5.38±0.46 | |
| End of study | 33.77±1.07 | 20.71±1.09 | Asafin | 32.28±0.71 | 20.71±1.09 | 35.08 | 16.57±1.16 | |

Statistical comparison of GSRS, Gastrointestinal Symptom Rating Scale; GDSS, Glasgow Dyspepsia Severity Score; and NDI, Nepean Dyspepsia Index values of Placebo with Asafin using paired sample t-test (within group) and independent sample t-test (between groups). The results are given as mean ± SEM. Values having a superscript significantly differ from its placebo at p<0.001. 95% CI values and mean difference comparison are also given.
the most beneficial effects were observed in bloating, postprandial fullness, early satiety, constipation, and indigestion, which were found to be significantly reduced from second week of the study period onwards. The percentage of people who reported more than 50% reduction in their discomfort levels were given in Table S2. Upon completion of the study, the relative percentage of subjects who reported more than 80% reduction were in bloating (58%), appetite (69%), postprandial fullness (74%), motion sickness (75%), and digestion (77%) for Asafin treated group as compared to less than 10% nonspecific improvement reported in the placebo group. It is also noted that 66% of subjects in Asafin group remained symptoms-free and 75% of the subjects reported an improvement in their ability and/or interest to carry out daily works with more stability and focus of mind due to the reduction in the frequency of FD symptoms. Almost 87% reported no usage of any synthetic drugs during the course of the study.

3.2. Safety Evaluation Studies. Within group comparison and between groups comparison results of haematological and biochemical analysis were given in Table 5. It was observed that the treatment of both Asafin and placebo did not produce any significant (p > 0.05) changes on haemoglobin content, RBC count, PCV, MCV, MCH, and MCHC concentrations as compared to the baseline values. Biochemical parameters such as liver-function markers (SGOT, SGPT, and ALP) and the renal function marker, (serum creatinine) also remained within the normal range upon treatment with both Asafin and placebo.

4. Discussion

Good digestion is an essential component for a good quality of life and well-being, since the digestive system is responsible for the retention of the nutrients and elimination of the waste. A variety of reasons including, but not limited to, sedentary life style, lack of exercise, food intake without appetite, irregularity in breakfast, chronic alcoholism, smoking, stress/anxiety, and oily food were found to induce gastrointestinal disorders, in addition to the pathogenesis of some diseases. FD is one of the most common digestive upset and its prevalence has been reported to vary from 11 to 30% among adult population [6]. Since FD is not life-threatening, it is not surprising that the primary choice of treatment option is the alternative therapies with natural agents widely used in various traditional systems of medicine. Though a number of botanical supplements are currently available for gut health, the majority of them have failed to provide satisfactory efficacy. Unstandardized solvent extraction techniques followed by harsh conditions of formulations of botanical extracts may be the main reasons for the lack of efficacy of botanical extracts. In the present study, a food-grade oleo-gum-resin of asafoetida, a GRAS-listed (Generally Recognised as Safe) kitchen spice widely used in India and other Asian countries, was employed. Considering the unpleasant organoleptic characteristics and sticky paste-like form of the natural asafoetida gum, a green formulation (Asafin) employing the fenugreek soluble dietary fibre (galactomannans) and water was used in the present study. Water based process of impregnation of asafoetida oleo-gum-resin into the soluble dietary fibre matrix under mild conditions of temperature under vacuum to provide free-flowing water soluble powder of Asafin and its characterization, stability, and controlled-release properties has recently been published [31]. Though the meaning of the Latin word “assa-foetida” itself is “Carrier of bad smell” with its common name as “Devils’ dunk” indicating the degree of unpleasant flavour characteristics of asafoetida oleo-gum-resin, uniform impregnation of the lipophilic gum into the hydrophilic matrix of the dietary fibre was found to provide taste and odour masked Asafin particles suitable for dietary applications.

Except the recent in vivo study on the gastroprotective effect of asafoetida gum by Babaean et al., no detailed reports (in vitro or in vivo) have been available on the gastroprotective effect and mechanism of action of asafoetida. Recently, we had reported the antioxidant, anti-inflammatory, and antiulcerogenic activities of Asafin on alcohol-induced ulcer model of rats [31]. While the antioxidant and anti-inflammatory activities were marginal, Asafin exhibited antiulcerogenic activity and safety with a significant enhancement in the gastric mucosa production [31]. The present randomized, placebo-controlled, and double-blinded pilot study employed Asafin containing about 42% (w/w) asafoetida-gum-oleo-resin formulated with debitterised fenugreek powder rich in soluble dietary fibre, so that each 250 mg capsules of Asafin provided 90±5 mg of asafoetida-gum. When supplementing two capsules per day (180±10 mg of asafoetida gum/day), the subjects with moderate to severe FD symptoms were found to have significant reduction in the gut disorders with an improvement in the quality of life as compared to placebo. While the FD symptoms were rated with well-validated symptoms scores scales (GSRS, GDSS, and NDI), 69% of the subjects reported to have significant reduction in symptoms scores with 87% of the subjects reporting no usage of synthetic drugs during the study period, as compared to the placebo group where 61% of the subjects reported the repeated use of synthetic drugs during the course of the study.

The GSRS is one of the most established and responsive disease-specific instrument with five symptom clusters depicting reflux, abdominal pain, indigestion, diarrhoea, and constipation. The seven-point graded Likert-type scale in GSRS with ascending order of severity of the symptoms has widely been used in FD studies [46, 47]. In the present study, Asafin treatment for 30 days showed significant (p ≤ 0.05) improvement in both inner and intergroup comparisons as compared to the placebo. The improvements in symptom scores and severity score were also clear from the other two scales (GDSS and NDI) used in the present study. GDSS has been well-validated as a global measurement of the severity of dyspepsia in patients with upper gastrointestinal disorders and has been shown to provide valuable responses on treatment [39]. A large number of studies have been globally reported in validating GDSS and used widely to evaluate the treatment efficacy [40, 48]. The fact that the present study provided highly significant beneficial response (p ≤0.001) with more than 50% reduction in severity scores for more
Table 5: Results of safety evaluation studies.

| Parameters                  | Intergroup comparison based on independent sample t-test | Inner group comparison based on paired sample t-test | Mean difference comparison of variables using independent sample t-test |
|-----------------------------|---------------------------------------------------------|-----------------------------------------------------|---------------------------------------------------------------------|
|                             | Time of Observation | Placebo | Asafin | Groups | Baseline | End of Study | Mean difference | p-value |
| Hb (g/dl)                   | Baseline           | 13.25±0.49 | 13.43±0.46 | Placebo | 13.26±0.17 | 13.20±0.82 | 0.06±0.04 | 0.219 |
|                             | End of study       | 13.20±0.47 | 13.78±0.49 | Asafin  | 13.45±0.15 | 13.78±0.20 | 0.33±0.05 | 0.940 |
| RBC Count (million/μL)     | Baseline           | 4.24±0.15 | 4.26±0.15 | Placebo | 4.25±0.37 | 4.25±0.33 | 0.09±0.02 | 0.003±0.02 |
|                             | End of study       | 4.25±0.16 | 4.25±0.15 | Asafin  | 4.26±0.06 | 4.26±0.04 | 0.50±0.13 | 0.261 |
| Packed cell volume (%)     | Baseline           | 38.30±0.36 | 39.22±0.45 | Placebo | 38.31±0.42 | 38.82±0.38 | 0.50±0.13 | 0.66±0.18 |
|                             | End of study       | 38.82±0.36 | 39.88±0.40 | Asafin  | 39.22±0.50 | 39.88±0.47 | 0.50±0.13 | 0.66±0.18 |
| Mean corpuscular volume     | Baseline           | 90.60±0.22 | 91.82±0.24 | Placebo | 90.61±0.84 | 91.02±0.88 | 0.40±0.12 | 0.067 |
| (fl/red cell)               | End of study       | 91.02±0.25 | 92.92±0.23 | Asafin  | 91.83±0.56 | 92.93±0.47 | 1.09±0.25 | 0.813 |
| Mean corpuscular haemoglobin | Baseline           | 31.32±0.13 | 31.52±0.27 | Placebo | 31.33±0.24 | 31.25±0.23 | 0.07±0.22 | 0.08±0.17 |
| (pg/cell)                   | End of study       | 31.25±0.48 | 31.71±0.19 | Asafin  | 31.52±0.20 | 31.71±0.13 | 0.09±0.17 | 0.813 |
| Mean corpuscular haemoglobin | Baseline           | 34.42±0.25 | 34.32±0.18 | Placebo | 34.42±0.18 | 34.09±0.21 | 0.03±0.05 | 0.477 |
| Concentration (g/dl)        | End of study       | 34.09±0.22 | 34.24±0.17 | Asafin  | 34.33±0.20 | 34.24±0.23 | 0.08±0.13 | 0.001 |
| SGOT (IU/L)                 | Baseline           | 25.46±0.93 | 27.18±0.93 | Placebo | 25.46±1.00 | 26.28±0.75 | 0.82±0.15 | 0.771 |
|                             | End of study       | 26.28±0.93 | 25.65±0.90 | Asafin  | 27.18±1.20 | 25.66±1.07 | 1.52±0.18 | 0.001 |
| SGPT (IU/L)                 | Baseline           | 33.27±1.22 | 35.14±1.21 | Placebo | 33.28±0.94 | 38.71±0.96 | 5.43±0.25 | 0.68±0.11 |
|                             | End of study       | 38.71±1.93 | 33.65±1.17 | Asafin  | 35.14±1.74 | 33.66±1.39 | 1.48±0.11 | 0.001 |
| ALP (IU/L)                  | Baseline           | 85.32±2.97 | 94.82±2.10 | Placebo | 85.32±2.12 | 95.33±2.07 | 10.20±0.52 | 0.027 |
|                             | End of study       | 95.53±2.33 | 95.11±2.57 | Asafin  | 89.92±2.50 | 95.11±2.57 | 5.19±0.30 | 0.006 |
| S. Creatinine (mg/dl)       | Baseline           | 0.77±0.02 | 0.82±0.02 | Placebo | 0.78±0.02 | 0.81±0.02 | 0.02±0.00 | 0.006 |
|                             | End of study       | 0.81±0.02 | 0.76±0.02 | Asafin  | 0.81±0.02 | 0.77±0.02 | 0.06±0.01 | 0.006 |

Values are expressed as mean ± SEM. Hb: haemoglobin, RBC: red blood cells, SGOT: serum glutamic oxaloacetic transaminase, SGPT: serum glutamic pyruvic transaminase, ALP: alkaline phosphatase and S.Creatinine: serum creatinine. Within group comparison was done using paired sample t-test and between group comparisons were done with independent sample t-test. Mean difference comparison of variables was performed by independent sample t-test. P value is also provided.
than 80% of subjects in the Asafin group demonstrates the efficacy of Asafin over the placebo group with only less than 13% improvement in the symptoms score. NDI is yet another most commonly used analysis tool for FD specifically to measure the symptoms and health-related quality of life [38]. NDI index was validated by Nkurunziza et al. and has been widely used in many recent studies [45, 49, 50]. In the present study, NDI scores were significantly reduced (47%) in Asafin treated group in comparison with the baseline values, whereas no significant change was observed in placebo.

It was also observed that almost 62% of subjects in the Asafin group showed >50% improvement in quality of life with a significant reduction in individual FD symptoms. Bloating, postprandial fullness, ability to eat, constipation, and digestion were the most significantly affected symptoms. Further, Asafin does not show any adverse effects or clinically significant changes in either haematological or biochemical parameters, indicating its safety and tolerance at the dosage of 250 mg × 2/day for 30 days. Thus, the present study demonstrated the safety and efficacy of asafoetida oleo-gum-resin and its gut health potential for the first time, paving the way forward with larger multicentred trials. However, relatively small number of patients and lack of endoscopic characterization of the patients remain as the drawbacks of the present study. Further studies involving 30 to 60 days of supplementation with at least one month of observation period and intervention on populations where asafoetida is not a regular part of the diet, such as in the West, will be of great interest.

5. Conclusion

Management of functional dyspepsia has always been a challenge due to the side effects and the cost associated with the synthetic drugs. The present double-blinded, placebo-controlled, randomized study on 43 subjects characterized with functional dyspepsia demonstrated the safety and efficacy of Ferula asafoetida oleo-gum-resin for the first time, when supplemented as a food-grade formulation with fenugreek dietary fibre (Asafin) for 30 days at a dosage of 250 mg × 2/day, containing around 36% (w/w) of asafoetida gum. While 81% of the subjects treated with Asafin showed significant improvement in overall symptoms score, 66% of the subjects remained symptoms-free at the end of the study. Almost 67% of the subjects in the Asafin group improved the quality of their life with better interest and focus on their daily works from the second week onwards with a significant improvement in bloating, postprandial fullness, food intake, heart burn, constipation, and digestion with no side effects or adverse events as demonstrated by the blood analysis.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors disclose the following conflicts of interest. Asafin™ is the registered trademark of M/s Akay Flavours & Aromatics Pvt. Ltd, India. Three of the coauthors were members of Akay Flavours & Aromatics Pvt. Ltd. And Dr. K. N. Mala who conducted the present study has no conflicts of interest.

Acknowledgments

The authors are grateful to M/s Akay Flavours & Aromatics Pvt. Ltd., India, for financial support and for the samples of Asafin produced in their GMP-certified manufacturing plant.

Supplementary Materials

Supplementary material 1: reduction in FD Symptom indexing Scores. Supplementary material 2: comparison of individual symptom scores. (Supplementary Materials)

References

[1] N. J. Talley, “Functional dyspepsia: advances in diagnosis and therapy,” Gut and Liver, vol. 11, no. 3, pp. 349–357, 2017.
[2] N. J. Talley and A. C. Ford, “Functional dyspepsia,” The New England Journal of Medicine, vol. 373, no. 19, pp. 1853–1863, 2015.
[3] P. Aro, N. J. Talley, L. Agréus et al., “Functional dyspepsia impairs quality of life in the adult population,” Alimentary Pharmacology & Therapeutics, vol. 33, no. 11, pp. 1215–1224, 2011.
[4] A. C. Ford, A. Marwaha, R. Sood, and P. Moayyedi, “Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis,” Gut, vol. 64, pp. 1049–1057, 2015.
[5] B. E. Lacy, K. T. Weiser, A. T. Kennedy, M. D. Crowell, and N. J. Talley, “Functional dyspepsia: the economic impact to patients,” Alimentary Pharmacology & Therapeutics, vol. 38, no. 2, pp. 170–177, 2013.
[6] S. Mahadeva and K. L. Goh, “Epidemiology of functional dyspepsia: a global perspective,” World Journal of Gastroenterology, vol. 12, no. 17, pp. 2661–2666, 2006.
[7] H. G. Ly, N. Weltens, J. Tack, and L. Van Oudenhove, “Acute anxiety and anxiety disorders are associated with impaired gastric accommodation in patients with functional dyspepsia,” Clinical Gastroenterology and Hepatology, vol. 13, no. 9, pp. 1584–1591, 2015.
[8] M. M. Walker, K. R. Aggarwal, L. S. Shim et al., “Duodenal eosinophilia and early satiety in functional dyspepsia: confirmation of a positive association in an Australian cohort,” Journal of Gastroenterology and Hepatology, vol. 29, no. 3, pp. 474–479, 2014.
[9] P. Iovino, C. Bucci, F. Tremolatera, A. Santonicola, and G. Chiarioni, “Bloating and functional gastro-intestinal disorders: where are we and where are we going?” World Journal of Gastroenterology, vol. 20, no. 39, pp. 14407–14419, 2014.
[10] L. E. Mazzoleni, G. B. Sander, C. F. D. M. Francesconi et al., “Helicobacter pylori eradication in functional dyspepsia: HEROES trial,” JAMA Internal Medicine, vol. 171, no. 21, pp. 1929–1936, 2011.
[11] P. Moayyedi, B. C. Delaney, N. Vakil, D. Forman, and N. J. Talley, “The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis,” Gastroenterology, vol. 127, no. 5, pp. 1329–1337, 2004.
[12] J. Tack, P. Janssen, T. Masaoka, R. Farré, and L. Van Oudenhove, “Efficacy of buspirone, a fundus-relaxing drug, in patients with...
functional dyspepsia," *Clinical Gastroenterology and Hepatology*, vol. 10, no. 11, pp. 1239–1245, 2012.

[13] E. M. Quigley, "Prokinetics in the management of functional gastrointestinal disorders," *Journal of Neurogastroenterology and Motility*, vol. 21, pp. 330–336, 2015.

[14] P. Moayyed and J. Mason, "Clinical and economic consequences of dyspepsia in the community," *Gut*, vol. 50, no. 4, pp. iv10–iv12, 2002.

[15] J. Tack, M. Camilleri, L. Chang et al., "Systematic review: cardiovascular safety profile of 5-HT4 agonists developed for gastrointestinal disorders," *Alimentary Pharmacology & Therapeutics*, vol. 35, no. 7, pp. 745–767, 2012.

[16] J. T. Coon and E. Ernst, "Systematic review: herbal medicinal products for non-ulcer dyspepsia," *Alimentary Pharmacology & Therapeutics*, vol. 16, no. 10, pp. 1689–1699, 2002.

[17] M. Babaeian, M. Naseri, M. Kamalinejad et al., "Herbal remedies for functional dyspepsia and traditional Iranian medicine perspective," *Iranian Red Crescent Medical Journal*, vol. 17, no. II, 2015.

[18] A. Sannia, "Phytotherapy with a mixture of dry extracts with herato-protective effects containing artichoke leaves in the management of functional dyspepsia symptoms," *Minerva Gastroenterologica e Dietologica*, vol. 56, no. 2, pp. 93–99, 2010.

[19] C. M. Habibullah, V. Chandra, C. Padmanabham, and R. Datla, "A double blind trial of deglycyrrhizinated liquorice in peptic ulcer," *The Indian Practitioner*, vol. 32, pp. 119–122, 1979.

[20] A. Giaconia, D. Guido, M. Grassi et al., "The effect of ginger (Zingiber officinale) and artichoke (Cynara cardunculus) extract supplementation on functional dyspepsia: a randomised, double-blind, and placebo-controlled clinical trial," *Evidence-Based Complementary and Alternative Medicine*, vol. 2015, Article ID 915087, 9 pages, 2015.

[21] M. Tariq, "Nigella sativa seeds: folk treatment in modern day medicine," *Saudi Journal of Gastroenterology*, vol. 14, no. 3, pp. 105–106, 2008.

[22] M. Rafei-kopaie and K. Hosseini-asl, "Effects of Ocimum basilicum on functional dyspepsia: a double-blind placebo-controlled study," *Iranian Journal of Medical Sciences*, vol. 30, no. 3, pp. 134–137, 2005.

[23] P. Mahendra and S. Bishet, "Ferula asafoetida: traditional uses and pharmacological activity," *Pharmacognosy Reviews*, vol. 6, no. 12, pp. 141–146, 2012.

[24] C.-H. Kao, Y.-H. Chu, and H.-W. Wang, "Effects of lidocaine on rat's isolated tracheal smooth muscle," *European Archives of Oto-Rhino-Laryngology*, vol. 267, no. 5, pp. 817–820, 2010.

[25] H. B. Mohammad, M. G. Rahbardar, and Z. Jafari, "The effect of safranal on histamine (H1) receptors of guinea pig tracheal chains," *Fitoterapia*, vol. 82, no. 2, pp. 162–167, 2011.

[26] S. J. Roberts, M. Papaioannou, B. A. Evans, and R. J. Summers, "Characterization of beta-adrenoceptor mediated smooth muscle relaxation and the detection of mRNA for beta1-, beta2- and beta3-adrenoceptors in rat ileum," *British Journal of Pharmacology*, vol. 127, no. 4, pp. 949–961, 1999.

[27] K. Van Crombruggen, L. Van Nassauw, J.-P. Timmermans, and R. A. Lefebvre, "Inhibitory purinergic P2 receptor characterisation in rat distal colon," *Neuropharmacology*, vol. 53, no. 2, pp. 257–271, 2007.

[28] M. G. Zizzo, F. Mulé, and R. Serio, "Functional evidence for GABA as modulator of the contractility of the longitudinal muscle in mouse duodenum: role of GABAA and GABAC receptors," *Neuropharmacology*, vol. 52, no. 8, pp. 1685–1690, 2007.

[29] Y. Kito and H. Suzuki, "Effects of Dai-kenchu-to on spontaneous activity in the mouse small intestine," *Journal of Smooth Muscle Research*, vol. 42, no. 6, pp. 189–201, 2006.

[30] M. Iranshahi and M. Iranshahi, "Traditional uses, phytochemistry and pharmacology of asafoetida (Ferula asafoetida oleo-gum-resin)—a review," *Journal of Ethnopharmacology*, vol. 134, no. 1, pp. 1–10, 2011.

[31] L. Vijayasteltar, I. J. Jismy, A. Joseph, B. Maliakel, R. Kuttan, and I. M. Krishnakumar, "Beyond the flavor: a green formulation of Ferula asafoetida oleo-gum-resin with fenugreek dietary fibre and its gut health potential," *Toxicology Reports*, vol. 4, pp. 382–390, 2017.

[32] D. Bano, H. Tabassum, A. Ahmad, A. Mabood, and I. Z. Ahmad, "The medicinal significance of the bioactive compounds of trigonella foenum-graecum: a review," *International Journal of Research in Ayurveda & Pharmacy*, vol. 7, no. 4, pp. 84–91, 2016.

[33] I. M. Krishnakumar, A. Ravi, D. Kumar, R. Kuttan, and B. Maliakel, "An enhanced bioavailable formulation of curcumin using fenugreek-derived soluble dietary fibre," *Journal of Functional Foods*, vol. 4, no. 1, pp. 348–357, 2012.

[34] "USP(361) Articles of botanical origin," http://www.pharmacopeia.cn/v29240/usp29nf24s0.

[35] *Steam Volatile Oil in Spices. Analytical Methods Manual*, vol. 5, American spice trade association Inc., Washington, DC, USA, 4th edition, 1997.

[36] J. Tack and N. J. Talley, "Functional dyspepsia—symptoms, definitions and validity of the Rome III criteria," *Nature Reviews Gastroenterology & Hepatology*, vol. 10, no. 3, pp. 134–141, 2013.

[37] K. R. Kulich, A. Madisch, F. Pacini et al., "Reliability and validity of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in dyspepsia: a six-country study," *Health and Quality of Life Outcomes*, vol. 6, no. 1, pp. 1–12, 2008.

[38] P. Neuvonen, J. Sand, M. Matikainen, and T. Rantanen, "Does nissen fundoplication provide lifelong reflux control? symptomatic outcome after 31–33 years," *World Journal of Surgery*, vol. 41, no. 8, pp. 2046–2052, 2017.

[39] E. M. El-Omar, S. Banerjee, A. Wirz, and K. E. L. McColl, "The Glasgow dyspepsia severity score—a tool for the global measurement of dyspepsia," *European Journal of Gastroenterology & Hepatology*, vol. 8, no. 10, pp. 967–971, 1996.

[40] A. Yazdanbod, S. Salimian, S. Habilzadeh, A. Hooshyar, N. Maleki, and M. Norouzvand, "Effect of Helicobacter pylori eradication in Iranian patients with functional dyspepsia: a prospective, randomized, placebo-controlled trial," *Archives of Medical Science*, vol. II, no. 5, pp. 964–969, 2015.

[41] N. J. Talley, M. Haque, J. W. Wyeth et al., "Development of a new dyspepsia impact scale: the Nepean Dyspepsia Index," *Alimentary Pharmacology & Therapeutics*, vol. 13, no. 2, pp. 225–235, 1999.

[42] X.-P. Tian, Y. Li, F.-R. Lianget al., "Translation and validation of the Chinese version of the Nepean Dyspepsia Index for functional dyspepsia in China," *World Journal of Gastroenterology*, vol. 23, no. 25, pp. 3173–3177, 2007.

[43] E. Dimenáš, H. Glise, B. Hallerbäck, H. Hernqvist, J. Svedlund, and I. Wiklund, "Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer," *Scandinavian Journal of Gastroenterology*, vol. 30, no. 11, pp. 1046–1052, 1995.

[44] P. Liu, G. Wang, F. Zeng et al., "Abnormal brain structure implicated in patients with functional dyspepsia," *Brain Imaging and Behaviour*, vol. 12, no. 2, pp. 456–466, 2018.
Evidence-Based Complementary and Alternative Medicine

[45] M. Azimi, F. Zolala, M. R. Baneshi, and M. J. Zahedi, “Validation of short-form Nepean Dyspepsia Index in Iranian patients with functional dyspepsia,” Govaresh, vol. 22, no. 2, pp. 17-18, 2017.

[46] D. Ang, N. J. Talley, M. Simren, P. Janssen, G. Boeckxstaens, and J. Tack, “Review article: endpoints used in functional dyspepsia drug therapy trials,” Alimentary Pharmacology & Therapeutics, vol. 33, no. 6, pp. 634–649, 2011.

[47] D. Khanna, R. D. Hays, A. B. Shreiner et al., “Responsiveness to change and minimally important differences of the patient-reported outcomes measurement information system gastrointestinal symptoms scales,” Digestive Diseases and Sciences, vol. 62, no. 5, pp. 1186–1192, 2017.

[48] H. Yamawaki, S. Futagami, M. Shimpuku et al., “Impact of sleep disorders, quality of life and gastric emptying in distinct subtypes of functional dyspepsia in Japan,” Journal of Neurogastroenterology and Motility, vol. 20, no. 1, pp. 104–112, 2014.

[49] A. Nkurunziza, V. Dusabejambo, K. Everhart, S. Bensen, and T. Walker, “Validation of the Kinyarwanda-version short-form Leeds dyspepsia questionnaire and short-form Nepean dyspepsia index to assess dyspepsia prevalence and quality-of-life impact in Rwanda,” BMJ Open, vol. 6, no. 6, 2016.

[50] J. Kim, J.-W. Park, S.-J. Ko et al., “Effects of a herbal medicine, Yukgunja-Tang, on functional dyspepsia patients classified by 3-dimensional facial measurement: a study protocol for placebo-controlled, double-blind, randomized trial,” Evidence-Based Complementary and Alternative Medicine, vol. 2017, Article ID 2894507, 8 pages, 2017.